Skip to content
All Sections
Subscribe Now
69°F
Wednesday, July 17th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
69°F
Wednesday, July 17th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Trump picks VP
Former LA County sheriff found
Food pantry for homeless pets
Anaheim to pay Angels $2.75M
LB Burger Week ð
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cyclo Therapeutics, Inc.
< Previous
1
2
Next >
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
June 25, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
May 30, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 18, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
March 14, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
January 29, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
December 27, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
AMTI
CYTH
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
December 18, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
November 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
November 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
October 23, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
October 05, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
September 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
AMTI
CYTH
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
August 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
August 02, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
June 29, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease
June 12, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
June 05, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
May 02, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
January 11, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
January 09, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
January 04, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
January 04, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
December 30, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
October 18, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
October 04, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Provides Business Update
September 28, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close